News
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $164.3
8 Apr 24
News, Price Target, Analyst Ratings
4 Analysts Assess BeiGene: What You Need To Know
27 Mar 24
Analyst Ratings
Bernstein Maintains Market Perform on BeiGene, Lowers Price Target to $161
27 Mar 24
News, Price Target, Analyst Ratings
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
22 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
15 Mar 24
Biotech, Large Cap, News, Health Care, FDA, General
BeiGene Secures FDA Approval For TEVIMBRA For Treatment Of Advanced Or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
14 Mar 24
News, FDA
FDA Approves Beigene's Tevimbra As Of March 13, 2024
14 Mar 24
News, FDA
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
13 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
13 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
8 Mar 24
Biotech, Large Cap, News, Health Care, FDA, General
BeiGene Announces Efficacy Analysis Comparing BRUKINSA To Acalabrutinib In Relapsed Or Refractory Chronic Lymphocytic Leukemia
29 Feb 24
Biotech, News, General
Guggenheim Maintains Buy on BeiGene, Lowers Price Target to $345
27 Feb 24
News, Price Target, Analyst Ratings
BeiGene's Biologics License Application for TEVIMBRA (Tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Bags FDA Approval
27 Feb 24
Government, News, Regulations
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Issued A Positive Opinion Recommending Approval Of BeiGene's Tislelizumab As A Treatment For Non-small Cell Lung Cancer Across Three Indications
26 Feb 24
Biotech, Large Cap, News, Health Care, General
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
20 Feb 24
Earnings, News
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
16 Feb 24
Asia, News, Markets, General
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
6 Feb 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Analyst Ratings, Movers, Trading Ideas, General
JP Morgan Assumes BeiGene at Overweight, Announces Price Target of $185
6 Feb 24
News, Price Target, Initiation, Analyst Ratings
Press releases
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
14 Mar 24
Press Releases
Thinking about trading options or stock in NVIDIA, Tesla, Oracle, Broadcom, or Beigene?
13 Mar 24
Opinion, Press Releases
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
13 Mar 24
Press Releases
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
7 Mar 24
Press Releases
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
6 Mar 24
Press Releases
BeiGene to Present at Upcoming Investor Conferences
28 Feb 24
Press Releases
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
27 Feb 24
Press Releases
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
Press Releases
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
26 Feb 24
Press Releases
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
7 Feb 24
Press Releases
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)
31 Jan 24
Press Releases
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
23 Jan 24
Press Releases